Cayston

"The National Institutes of Health has launched DS-Connect, a Web-based health registry that will serve as a national health resource for people with Down syndrome and their families, researchers, and health care providers.

Cayston

OVERDOSE

No overdoses have been reported with CAYSTON in clinical
trials to date. In clinical trials, 225 mg doses of CAYSTON via inhalation were
associated with higher rates of drug-related respiratory adverse reactions,
particularly cough. Since the peak plasma concentration of aztreonam following
administration of CAYSTON (75 mg) is approximately 0.6 mcg/mL, compared to a
serum concentration of 54 mcg/mL following administration of aztreonam for
injection (500 mg), no systemic safety issues associated with CAYSTON overdose
are anticipated.

CONTRAINDICATIONS

CAYSTON is contraindicated in patients with a known allergy
to aztreonam.

Last reviewed on RxList: 10/10/2012
This monograph has been modified to include the generic and brand name in many instances.